Literature DB >> 1122690

Pharmacokinetics of ifosfamide.

L M Allen, P J Creaven.   

Abstract

A multicompartment pharmacokinetic model for ifosfamide has been employed using a system of first-order differential equations, which includes a term for metabolism according to Michaelis-Menten kinetics in order to describe the distribution and elimination parameters of ifosfamide in man. The model satisfactorily accounts for all the administered drug. The pseudometabolic rate constant for ifosfamide in man is found to be less than 20 percent of that reported for cyclophosphamide in man, in agreement with the more extensive metabolism of cyclophosphamide than ifosfamide. A number of the pharmacokinetic parameters for ifosfamide differ substantially from those reported for cyclophosphamide. The volume of distribution for ifosfamide metabolites was found to be approximately equal to the plasma space volume. The central compartment volume for intact ifosfamide is slightly larger than for cyclophosphamide and includes the easily diffusible extravascular space of the body and suggests lack of protein binding. The renal clearance of ifosfamide is low and about twice that of cyclophosphamide. The model indicates that only a small fraction of the total metabolites distribute into the peripheral compartment and suggests that multiple doses of the drug may be useful.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1122690     DOI: 10.1002/cpt1975174492

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

Authors:  T Kerbusch; A D Huitema; J Ouwerkerk; H J Keizer; R A Mathôt; J H Schellens; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

3.  Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.

Authors:  J C Cervellino; C E Araujo; C Pirisi; O Sanchez; M Brosto; R Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.

Authors:  P A Philip; L D Lewis; C A James; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma.

Authors:  M E Heim; R Fiene; E Schick; E Wolpert; W Queisser
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

6.  New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.

Authors:  M P Di Marco; I W Wainer; C L Granvil; G Batist; M P Ducharme
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

7.  Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.

Authors:  S A Corlett; D Parker; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

8.  Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.

Authors:  C P Granvil; J Ducharme; B Leyland-Jones; M Trudeau; I W Wainer
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.

Authors:  Duan Wang; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2012-04-01       Impact factor: 11.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.